Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.10.1 (ERK)
 95,504 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fibroblast growth factors are structurally related proteins associated with cell growth, differentiation, migration, wound healing, angiogenesis, and oncogenesis. At the cellular level, their function is mediated by transmembrane tyrosinekinase receptors, fibroblast growth factor receptors. Four genes encoding fibroblast growth factor receptors have been identified, and mutations in three of these, FGFR1, FGFR2, and FGFR3, can cause different congenital, autosomal dominant disorders affecting the craniofacial and skeletal development: craniosynostosis and chondrodysplasias. The craniosynostosis syndromes: Apert syndrome, Beare-Stevenson syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Muenke syndrome, Pfeiffer syndrome and Saethre-Chotzen syndrome can be caused by mutation in either FGFR1, FGFR2, or FGFR3. Saethre-Chotzen syndrome can also be caused by mutation in a functionally related gene, ACS. The same mutation can cause different syndromes, and the same syndrome can be caused by mutations in different genes. The chondrodysplasias: achondroplasia, hypochondroplasia, and thanatophoric dysplasia are all caused by mutations in FGFR3.
 ...
PMID:[The molecular genetic background of hereditary craniosynostoses and chondrodysplasias]. 1157 61

Soluble ErbB (sErbB) growth factor receptors are being investigated as cancer biomarkers. Gonadotropic and steroid hormones have been shown to modulate the expression of ERBB family members in vivo. Accordingly, the range of sErbB1 values and their relationship to gonadotropic and steroid hormones need to be established in healthy subjects to provide a baseline for future clinical studies. We assayed sera from healthy men and women to determine p110 sErbB1 concentrations by acridinium-linked immunosorbent assay (ALISA). Follicle-stimulating hormone (FSH), estradiol, and testosterone concentrations were measured using the ACS:180 Immunoassay Analyzer. Luteinizing hormone (LH) and progesterone concentrations were quantified using the Access Immunoassay System. Unadjusted for age, p110 sErbB1 concentrations in healthy men and women do not differ significantly. However, sErbB1 concentrations show a strong age-gender interaction, increasing with age in men but decreasing with age in women. Consequently, sErbB1 concentrations are significantly higher in premenopausal women compared with either postmenopausal women or age-matched men and in age-matched men compared with postmenopausal women. Serum sErbB1 concentrations show significant negative associations with both FSH and LH concentrations in healthy women and a significant positive association with FSH concentrations in healthy men. Univariate linear regression models show that these respective gonadotropic hormones and age are independent predictors of sErbB1 concentrations in men and women. Multivariate models show that when age and FSH and LH concentrations are mutually adjusted for each other, they account for 22% of the variability observed in sErbB1 concentrations in healthy women. These data support the hypothesis that gonadotropic and steroid hormones may modulate ERBB1 expression in vivo and suggest that age- and gonadotropin-adjusted sErbB1 concentrations may be of clinical utility. Furthermore, these data demonstrate that gender, age, menstrual cycle phase, menopausal status, and exogenous hormone use must be considered when using serum p110 sErbB1 concentrations as cancer biomarkers.
 ...
PMID:A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. 1170 Feb 66

The article describes the methods for the correction of hypermetropia, i.e. micro-lamellar keratotomy (MLK) and MLK plus thermokeratocoagulation (MLKTKC). The experiment was made on 6 rabbits (12 eyes). Lamellar corneal incisions were implemented by ALK ACS system (USA) to a depth of 73-75% of the corneal thickness. Simultaneously, thermokeratocoagulation (TKC) to 80% of the corneal thickness was made in a part of animals in meridians 6, 8, 10 and 12 (an 8 mm optic zone and 3 to 4 coagulates in each meridian). Postoperatively, the keratometric data were evaluated in 1, 3 and 6 months. The corneal optic power went up, postoperatively, in the center by around 4.0 diopters in cases, when the common surgical technique was used, and it went up to 5.0-9.0 diopters, when the common technique was combined with TKC. A clinical approbation of the MLK and MLKTKC methods in adults with hypermetropia (44 operations, mean age 29.3 years) showed their efficiency and safety. The corneal refraction improvement ranged from 3.5 diopters to 7.5 diopters (mean 4.49 +/- 0.89 diopters). The developed method of the above surgeries (the diameter of the modeled optic zone is 5 mm, the lamellar depth incision is 73%) prevents the complications, which lead to irreversible changes of the cornea; besides, it makes it possible to preserve a sufficiently wide central optic zone with a present refraction. This study provided a foundation for the clinical use of the method in pediatric practice.
 ...
PMID:[Experimental-clinical substantiation of the use of micro-lamellar keratotomy combined with kerato-thermocoagulation in the correction of hypermetropia]. 1367 7

The American College of Surgeons Commission on Cancer (ACS-CoC) mandates that pathology reports at ACS-CoC-approved cancer programs include all scientifically validated data elements for each site and tumor specimen. The College of American Pathologists (CAP) has produced cancer checklists in static text formats to assist reporting. To be inclusive, the CAP checklists are pages long, requiring extensive text editing and multiple intermediate steps. We created a set of dynamic tumor-reporting templates, using Microsoft Active Server Page (ASP.NET), with drop-down list and data-compile features, and added a reminder function to indicate missing information. Users can access this system on the Internet, prepare the tumor report by selecting relevant data from drop-down lists with an embedded tumor staging scheme, and directly transfer the final report into a laboratory information system by using the copy-and-paste function. By minimizing extensive text editing and eliminating intermediate steps, this system can reduce reporting errors, improve work efficiency, and increase compliance.
 ...
PMID:Synoptic reporting in tumor pathology: advantages of a web-based system. 1750 81

A 10,000 member peptide nucleic acid (PNA) encoded peptide library was prepared, treated with the Abelson tyrosine kinase (Abl), and decoded using a DNA microarray and a fluorescently labeled secondary antiphosphotyrosine antibody. A dual-color approach ensured internal referencing for each and every member of the library and the generation of robust data sets. Analysis identified 155 peptides (out of 10,000) that were strongly phosphorylated by Abl in full agreement with known Abl specificities. BLAST analysis identified known cellular Abl substrates such as c-Jun amino-terminal kinase as well as new potential target proteins such as the G-protein coupled receptor kinase 6 and diacylglycerol kinase gamma. To illustrate the generalization of this approach, two other tyrosine kinases, human epidermal growth factor 2 (Her2) and vascular endothelial growth factor receptor 2/kinase insert domain protein receptor (VEGFR2/KDR), were profiled allowing characterization of specific peptide sequences known to interact with these kinases; under these conditions Her2 was demonstrated to have a marked preference for D-proline perhaps offering a unique means of targeting and inhibiting this kinase.
ACS Chem Biol 2007 Dec 21
PMID:A 10,000 member PNA-encoded peptide library for profiling tyrosine kinases. 1815 68

Molecules specifically designed to modulate protein-protein interactions have tremendous potential as novel therapeutic agents. One important anticancer target is the chaperone Hsp90, whose activity is essential for the folding of many oncogenic proteins, including HER2, IGFIR, AKT, RAF-1, and FLT-3. Here we report the design and characterization of new tetratricopeptide repeat modules, which bind to the C-terminus of Hsp90 with higher affinity and with greater specificity than natural Hsp90-binding co-chaperones. Thus, when these modules are introduced into the cell, they out-compete endogenous co-chaperones for binding, thereby inhibiting Hsp90 function. The effect of Hsp90 inhibition in this fashion is dramatic; HER2 levels are substantially decreased and BT474 HER2 positive breast cancer cells are killed. Our designs thus provide new tools with which to dissect the mechanism of Hsp90-mediated protein folding and also open the door to the development of an entirely new class of anticancer agents.
ACS Chem Biol 2008 Mar 20
PMID:Designed TPR modules as novel anticancer agents. 1835 5

Unregulated cellular proliferation, caused by mutation or dysregulation of growth-promoting proteins, is an underlying cause of cancer. Many such growth-promoting proteins exhibit an increased dependence on the activity of the chaperone heat-shock protein 90 (Hsp90) for correct folding and maturation in the cell. One can therefore envision that inhibition of Hsp90 would be an effective and broadly applicable strategy for the development of anticancer agents. Hsp90 functions in multichaperone complexes driven by the binding and hydrolysis of ATP. Encouraging results have been obtained by inhibiting Hsp90 with 17-AAG, an active-site binding ATP analog. Here we present the results of a different approach to inhibiting Hsp90 by disrupting its interaction with a cochaperone named Hsp organizing protein (HOP). We have used an AlphaScreen technology based high-throughput in vitro screen to identify compounds that inhibit this interaction. In addition, we demonstrate that these compounds are active in vivo. Treatment of human breast cancer cell lines BT474 and SKBR3 with these compounds decreases the levels of the Hsp90-dependent client protein HER2, with associated cell death.
ACS Chem Biol 2008 Oct 17
PMID:A novel class of small molecule inhibitors of Hsp90. 1878 42

Gold nanocages with an average edge length of 65 +/- 7 nm and a strong absorption peak at 800 nm were conjugated with monoclonal antibodies (anti-HER2) to target breast cancer cells (SK-BR-3) through the epidermal growth factor receptor (in this case, HER2), which is overexpressed on the surfaces of the cells. Both the number of immuno Au nanocages immobilized per cell and the photothermal therapeutic effect were quantified using flow cytometry. The targeted cells were irradiated with a pulsed near-infrared laser, and by varying the power density, the duration of laser exposure, and the time of response after irradiation, we were able to optimize the treatment conditions to achieve effective destruction of the cancer cells. We found that cells targeted with the immuno Au nanocages responded immediately to laser irradiation and that the cellular damage was irreversible at power densities greater than 1.6 W/cm(2). The percentage of dead cells increased with increasing exposure time up to 5 min and then became steady. By quantifying the photothermal effect of immuno Au nanocages, critical information with regards to both the optimal dosage of nanocages and parameters of the laser irradiation has been garnered and will be applied to future in vivo studies.
ACS Nano 2008 Aug
PMID:A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. 1920 68

Six materials, (EDT-TTF)(4)BrI(2)(TIE)(5) (1, where EDT-TTF = ethylenedithiotetrathiafulvalene and TIE = tetraiodoethylene), (EDST)(4)I(3)(TIE)(5) (2, where EDST = ethylenedithiodiselenadithiafulvalene), (MDT-TTF)(4)BrI(2)(TIE)(5) (3, where MDT-TTF = methylenedithiotetrathiafulvalene), (HMTSF)(2)Cl(2)(TIE)(3) (4, where HMTSF = hexamethylenetetraselenafulvalene), (PT)(2)Cl(DFBIB)(2) (5, where PT = bis(propylenedithio)tetrathiafulvalene and DFBIB = 1,4-difluoro-2,5-bis(iodoethynyl)benzene), and (TSF)Cl(HFTIEB) (6, where TSF = tetraselenafulvalene and HFTIEB = 1,1',3,3',5,5'-hexafluoro-2,2',4,4'-tris(iodoethynyl)-biphenyl), consisting of conducting nanowires were obtained by galvanostatic oxidation of the donor molecules in the presence of the corresponding halide anions and iodine-containing neutral molecules. We report their characterizations using single-crystal crystallography, electrical resistance measurements, and electron spin resonance. The structures are built on stacks of planar cations of the donors that are isolated electrically by an insulating network consisting of supramolecular assemblies of the halide anions and neutral molecules held together by a halogen bond. The size and shape as well as the orientation (tilt) of the donors are matched by the self-organization of the insulating sheaths in all cases, providing a pea-in-a-pod example in the field of supramolecular chemistry. The observed resistivities, resistivity anisotropies, and electron spin resonance behaviors of these salts are analyzed by tight-binding band calculations and resistance-array modeling. Crystal 6 with insulating layer of 1 nm thickness exhibits 8 orders of magnitude anisotropy in its resistivity, indicating high potential of the supramolecular network as sheathing material. The observation of such networks leads us to propose a roadmap for future development toward multidimensional memory devices.
ACS Nano 2008 Jan
PMID:Supramolecular insulating networks sheathing conducting nanowires based on organic radical cations. 1920 58

We present the integration of amphiphilic block copolymer micelles as nanometer-sized vehicles for hydrophobic drugs within layer-by-layer (LbL) films using alternating hydrogen bond interactions as the driving force for assembly for the first time, thus enabling the incorporation of drugs and pH-sensitive release. The film was constructed based on the hydrogen bonding between poly(acrylic acid) (PAA) as an H-bond donor and biodegradable poly(ethylene oxide)-block-poly(epsilon-caprolactone) (PEO-b-PCL) micelles as the H-bond acceptor when assembled under acidic conditions. By taking advantage of the weak interactions of the hydrogen-bonded film on hydrophobic surfaces, it is possible to generate flexible free-standing films of these materials. A free-standing micelle LbL film of (PEO-b-PCL/PAA)60 with a thickness of 3.1 microm was isolated, allowing further characterization of the bulk film properties, including morphology and phase transitions, using transmission electron microscopy and differential scanning calorimetry. Because of the sensitive nature of the hydrogen bonding employed to build the multilayers, the film can be rapidly deconstructed to release micelles upon exposure to physiological conditions. However, we could also successfully control the rate of film deconstruction by cross-linking carboxylic acid groups in PAA through thermally induced anhydride linkages, which retard the drug release to the surrounding medium to enable sustained release over multiple days. To demonstrate efficacy in delivering active therapeutics, in vitro Kirby-Bauer assays against Staphylococcus aureus were used to illustrate that the drug-loaded micelle LbL film can release significant amounts of an active antibacterial drug, triclosan, to inhibit the growth of bacteria. Because the micellar encapsulation of hydrophobic therapeutics does not require specific chemical interactions, we believe this noncovalent approach provides a new route to integrating active small, uncharged, and hydrophobic therapeutics into LbL thin films for biological and biomedical coatings.
ACS Nano 2008 Feb
PMID:Hydrogen-bonding layer-by-layer-assembled biodegradable polymeric micelles as drug delivery vehicles from surfaces. 1920 41


1 2 3 4 5 6 7 8 9 10 Next >>